Compare LVS & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVS | ZTS |
|---|---|---|
| Founded | 1988 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 32.5B |
| IPO Year | 2004 | 2012 |
| Metric | LVS | ZTS |
|---|---|---|
| Price | $44.53 | $75.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $69.21 | ★ $154.18 |
| AVG Volume (30 Days) | 4.1M | ★ 4.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.23% | 1.86% |
| EPS Growth | ★ 19.90 | 10.05 |
| EPS | 1.38 | ★ 3.08 |
| Revenue | ★ $13,017,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $7.24 | $5.63 |
| Revenue Next Year | $4.49 | $4.77 |
| P/E Ratio | $32.32 | ★ $24.82 |
| Revenue Growth | ★ 15.22 | 2.28 |
| 52 Week Low | $43.36 | $71.00 |
| 52 Week High | $70.45 | $149.75 |
| Indicator | LVS | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 50.81 |
| Support Level | $44.58 | $73.02 |
| Resistance Level | $54.81 | $78.74 |
| Average True Range (ATR) | 1.23 | 2.21 |
| MACD | -0.16 | 0.14 |
| Stochastic Oscillator | 29.87 | 70.32 |
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, Sands generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.